The Role of Ischemia Reversal Program and Dietary Restriction in Improving Quality of Life by Reducing Myocardial Ischemia and Risk of Heart Disease

Yogita Patil *

Madhavbaug Clinic - Virar West, Maharashtra, India.

Bipin Gond

Madhavbaug Clinics, Western Mumbai, Marathwada, Madhya Pradesh and Delhi NCR Zone, India.

*Author to whom correspondence should be addressed.


Background: Curbing the prevalence rates of ischemia heart disease presents a formidable challenge owing to a complex interplay of determinants such as low diagnostic rates, poor patient medication adherence, and less practice of evidence-based interventions. Ischemia Reversal Program (IRP) is an alternative therapy for ischemic heart disease patients, it is a combination of Panchakarma and allied therapy. The study intended to assess the role of IRP in improving quality of life by reducing myocardial ischemia and risk of heart disease.

Methods: A prospective, observational, single-centre study was conducted at Madhavbaug Cardiac Care Clinic from March 2021 to December 2022. Patients aged 18 years and above diagnosed with ischemic heart disease and that had participated in the IRP for a minimum of 7 sessions over a 90-day duration were included in this study. Data at baseline was compared with data at the 90-day follow-up.

Results: Of the 35 patients screened, 23 patients were included in the present study. Mean age of the study patients was 55.30 ± 8.01 years and 78.3% were male. The VO2 peak significantly improved from 17.53 ± 9.17 on day 1 to 26.93 ± 7.71 at day 90.

Conclusion: The IRP can be an effective treatment to reduce risk of mortality due to heart disease and to improve quality of life in stable ischemic heart disease patients.

Keywords: Ayurveda, coronary artery disease, ischemic heart disease, Panchakarma, VO2 peak

How to Cite

Patil , Y., & Gond , B. (2023). The Role of Ischemia Reversal Program and Dietary Restriction in Improving Quality of Life by Reducing Myocardial Ischemia and Risk of Heart Disease. Asian Journal of Cardiology Research, 6(1), 252–258. Retrieved from


Download data is not yet available.


Bhattacharjee S, Yaghmaei N, Phuong CTL, Neupane D. Factors influencing the readiness to tackle the burden of ischaemic heart disease in India: a systematic review protocol. BMJ Open. 2021;11(8):e047464.

Sane R, Gond B, Raje G, Walzade K, Badre A, Mandole R. Ischemia Reversal Program (IRP) in patients suffering from Ischemic Heart Disease (IHD) with known history of Hypertension: A Retrospective Study. J Ayurveda Med Sci. 2018;3(2): 377–83.

O’Connor PJ. Improving medication adherence: challenges for physicians, payers, and policy makers: Challenges for physicians, payers, and policy makers. Arch Intern Med. 2006;166(17):1802–4.

Sane R, Sugwekar V, Nadapude A, Hande A, Depe G, Mandole R. Study of efficacy of ischemia reversal program (IRP) in ischemic heart disease (IHD) patients with VO2max and Duke’s treadmill score. Int J Basic Clin Pharmacol. 2018;7(8):1642.

Pandey MM, Rastogi S, Rawat AKS. Indian traditional ayurvedic system of medicine and nutritional supplementation. Evid Based Complement Alternat Med. 2013; 2013: 376327.

Dixon JR. Jr The International Conference on Harmonization Good Clinical Practice guideline. Qual Assur. 1998;6:65–74.

General Assembly of the World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent. 2014 Summer; 81(3):14–8.

Lairikyengbam SKS, Davies AG. Interpreting exercise treadmill tests needs scoring system. BMJ. 2002;325(7361):443.

Sane R, Wadekar A, Shinde K. Understanding the role of Ayurveda based ischemia reversal program and low carbohydrate diet in reduction of risk of heart disease. Asian Journal of Cardiovascular Research. 2019;2(1):1–8.

Sarbere L, Khan S, Sarbere P. Efficacy of ischemic reversal program in stable ischemic heart disease patients tom improve quality of life. Asian Journal of Cardiovascular Research. 2023;8(3):6–11.

Špinar J. Hypertension and ischemic heart disease. Cor Vasa. 2012;54(11–12): e433–8.

Liu S, Luo J, Zhang T, Zhang D, Zhang H. The combined role of obesity and depressive symptoms in the association with ischaemic heart disease and its subtypes. Sci Rep. 2022;12(1):14419.

Logue J, Murray HM, Welsh P, Shepherd J, Packard C, Macfarlane P, et al. Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation. Heart. 2011; 97(7):564–8.

Lau DCW, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005; 288(5):H2031-41.

Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009;6(6):399–409.

Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340(2): 115–26.